Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20249
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZikou, A. K.en
dc.contributor.authorArgyropoulou, M. I.en
dc.contributor.authorVoulgari, P. V.en
dc.contributor.authorXydis, V. G.en
dc.contributor.authorNikas, S. N.en
dc.contributor.authorEfremidis, S. C.en
dc.contributor.authorDrosos, A. A.en
dc.date.accessioned2015-11-24T19:05:49Z-
dc.date.available2015-11-24T19:05:49Z-
dc.identifier.issn0315-162X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20249-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibodies, Monoclonal/*therapeutic useen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntirheumatic Agents/*therapeutic useen
dc.subjectArthritis, Rheumatoid/*drug therapy/*pathology/physiopathologyen
dc.subjectContrast Mediaen
dc.subjectFemaleen
dc.subjectGadolinium DTPA/diagnostic useen
dc.subjectHand Joints/*pathologyen
dc.subjectHumansen
dc.subject*Magnetic Resonance Imagingen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectSynovitis/*pathologyen
dc.subjectTreatment Outcomeen
dc.subjectTumor Necrosis Factor-alpha/*antagonists & inhibitorsen
dc.titleMagnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumaben
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16465650-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2006-
heal.abstractOBJECTIVE: To investigate the clinical response and to evaluate by magnetic resonance imaging (MRI) the inflammatory tissue changes in patients with refractory rheumatoid arthritis (RA) treated with adalimumab. METHODS: Thirteen patients with refractory RA who were treated with adalimumab (40 mg every 2 weeks subcutaneously) were examined with MRI of the dominant affected wrist and hand before treatment and one year after therapy. The volume of the enhanced inflammatory tissue (VEIT) was evaluated in fat-suppressed contrast-enhanced T1-weighted MRI images using the Analyse 4.0 software. Disease activity was evaluated using the Disease Activity Score 28-joint (DAS-28). Clinical improvement was evaluated according to the American College of Rheumatology 20% response criteria (ACR20%). RESULTS: We studied 12 women and one man, with mean age 52.0 +/- 10.9 years and mean disease duration 13.0 +/- 8.5 years. Eight patients had positive IgM rheumatoid factor. One year after treatment, 11 (84.6%) patients showed a decrease of the VEIT. Moreover the values of C-reactive protein (CRP; 4.3 +/- 6.6 mg/l), the erythrocyte sedimentation rate (ESR; 26.3 +/- 19.5 mm/h), the DAS-28 (3.5 +/- 1.1), and the VEIT (21.6 +/- 10.7 cm3) after treatment were significantly lower compared to the corresponding values before treatment (CRP 41.6 +/- 39.2), (ESR 54.3 +/- 28.6) (DAS-28 5.8 +/- 0.8), and (VEIT 36.9 +/- 16.8) (p < 0.01). All but 3 (76.9%) patients with RA achieved the ACR20% response, while 7 (53.8%) and 5 (38.5%) patients achieved ACR50% and ACR70% response, respectively. A positive correlation between VEIT, swollen joint count, and ESR was found before treatment (r = 0.59, r = 0.64, respectively; p < 0.05). CONCLUSION: In patients with refractory RA, treatment with adalimumab resulted in improvement of clinical, laboratory, and MRI findings. MRI assessment of the VEIT may represent an additional tool for investigation of joint disease activity and responsiveness to treatment.en
heal.journalNameJ Rheumatolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons